1. Construction and Immunogenicity of a Recombinant Porcine Pseudorabies Virus (PRV) Expressing the Major Neutralizing Epitope Regions of S1 Protein of Variant PEDV.
- Author
-
Jiao XQ, Liu Y, Chen XM, Wang CY, Cui JT, Zheng LL, Ma SJ, and Chen HY
- Subjects
- Animals, Swine, Pseudorabies prevention & control, Pseudorabies immunology, Vaccines, Synthetic immunology, Vaccines, Synthetic genetics, Vaccines, Synthetic administration & dosage, Porcine epidemic diarrhea virus immunology, Porcine epidemic diarrhea virus genetics, Herpesvirus 1, Suid immunology, Herpesvirus 1, Suid genetics, Swine Diseases prevention & control, Swine Diseases virology, Swine Diseases immunology, Antibodies, Viral blood, Antibodies, Viral immunology, Viral Vaccines immunology, Viral Vaccines genetics, Epitopes immunology, Epitopes genetics, Coronavirus Infections prevention & control, Coronavirus Infections veterinary, Coronavirus Infections immunology, Coronavirus Infections virology, Antibodies, Neutralizing blood, Antibodies, Neutralizing immunology, Spike Glycoprotein, Coronavirus immunology, Spike Glycoprotein, Coronavirus genetics
- Abstract
Porcine epidemic diarrhea virus (PEDV) infection causes severe diarrhea and high mortality in neonatal piglets. Pseudorabies causes acute and often fatal infections in young piglets, respiratory disorders in growing pigs, and reproductive failure in sows. In late 2011, pseudorabies virus (PRV) variants occurred in Bartha-K61-vaccine-immunized swine herds, resulting in economic losses to the global pig industry. Therefore, it is essential to develop a safe and effective vaccine against both PEDV and PRV infections. In this study, we constructed a recombinant virus rPRV-PEDV S1 expressing the major neutralizing epitope region (COE, SS2, and SS6) of the PEDV S1 protein by homologous recombination technology and CRISPR/Cas9 gene editing technology, and then evaluated its biological characteristics in vitro and immunogenicity in pigs. The recombinant virus rPRV-PEDV S1 had similar growth kinetics in vitro to the parental rPRV NY-gE
- /gI- /TK- strain, and was proven genetically stable in swine testicle (ST) cells and safe for piglets. PEDV S1-specific antibodies were detected in piglets immunized with rPRV-PEDV S1 on the 7th day post-immunization (dpi), and the antibody level increased rapidly at 14-21 dpi. Moreover, the immunized piglets receiving the recombinant virus exhibited alleviated clinical signs and reduced viral load compared to the unvaccinated group following a virulent PEDV HN2021 strain challenge. Also, piglets immunized with rPRV-PEDV S1 developed a PRV-specific humoral immune response and elicited complete protection against a lethal PRV NY challenge. These data indicate that the recombinant rPRV-PEDV S1 is a promising vaccine candidate strain for the prevention and control of PEDV and PRV infections.- Published
- 2024
- Full Text
- View/download PDF